90390-07-1

Usage

Uses

Used in Organic Synthesis:
N-METHYL-N-[3-(TRIFLUOROMETHYL)BENZYL]AMINE is used as a reagent for the formation of amides and other nitrogen-containing organic compounds, playing a crucial role in the synthesis of complex molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, N-METHYL-N-[3-(TRIFLUOROMETHYL)BENZYL]AMINE is utilized as a building block for the synthesis of pharmaceutical compounds, leveraging its unique reactivity to modify the properties of organic molecules and enhance their therapeutic effects.
Used in Agrochemical Industry:
N-METHYL-N-[3-(TRIFLUOROMETHYL)BENZYL]AMINE also finds application in the agrochemical industry, where it serves as a key component in the development of agrochemical products, contributing to the improvement of their efficacy and selectivity.

InChI:InChI=1/C9H10F3N/c1-13-6-7-3-2-4-8(5-7)9(10,11)12/h2-5,13H,6H2,1H3

Upstream product

• 121372-62-1 Methyl-[1-(3-trifluoromethyl-phenyl)-meth-(E)-ylidene]-amine 
• 74-89-5 methylamine 
• 402-23-3 1-bromomethyl-3-trifluoromethylbenzene 
• 705-29-3 3-Trifluoromethylbenzyl chloride 
• 454-89-7 3-Trifluoromethylbenzaldehyde 

Downstream Products

• 76532-18-8 N⁶-Methyl-N⁶-(3-trifluoromethyl-benzyl)-pteridine-2,4,6-triamine 
• 98736-48-2 C₉H₉F₃N₂O 
• 512785-12-5 N-benzyloxycarbonyl-D-aspartic acid γ-tert-butyl ester α-[N-methyl-N-(3-trifluoromethylbenzyl)]amide 
• 866782-20-9 ((R)-2-(2-fluoro-phenyl)-1-{[methyl-(3-trifluoromethyl-benzyl)-sulphamoyl]-methyl}-ethyl)-carbamic acid benzyl ester 
• 957113-00-7 C₃₅H₄₃F₄N₃O₆ 
• 1224392-14-6 N-Methyl-4-oxo-4-(4-phenyl-6,7-dihydro-thieno[3,2-c]pyridin-5(4H)-yl)-N-(3-(trifluoromethyl)benzyl)butanamide 
• 1453069-72-1 (1S,8aS)-7,7-diallyl-N-methyl-6-oxo-1-o-tolyl-N-(3-(trifluoromethyl)benzyl)hexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxamide 
• 1453068-18-2 N-methyl-1-(2-methylphenyl)-6-oxo-N-{[3-(trifluoromethyl)phenyl]methyl}octahydropyrrolo[1,2-a]piperazine-2-carboxamide 
• 1453068-17-1 N-methyl-1-(2-methylphenyl)-6-oxo-N-{[3-(trifluoromethyl)phenyl]methyl}octahydropyrrolo[1,2-a]piperazine-2-carboxamide 
• 1453068-93-3 (1S,8aS)-7,7-bis(2-hydroxyethyl)-N-methyl-6-oxo-1-o-tolyl-N-(3-(trifluoromethyl)benzyl)hexahydropyrrolo[1,2-a]pyrazine-2(1H)-carboxamide 
• 512784-94-0 SRX₂₅₁ 
• 512785-22-7 N-methyl-3-[2-oxo-3-(2-oxo-4-phenyl-oxazolidin-3-yl)-4-styryl-azetidin-1-yl]-N-(3-trifluoromethyl-benzyl)-succinamic acid tert-butyl ester 
• 512785-30-7 N-methyl-3-[2-oxo-3-(2-oxo-4-phenyl-oxazolidin-3-yl)-4-styryl-azetidin-1-yl]-N-(3-trifluoromethyl-benzyl)-succinamic acid 
• 512785-17-0 D-aspartic acid β-tert-butyl ester α-N-methyl-N-[3-(trifluoromethyl)benzyl]amide 

Relevant academic research and scientific papers

NOVEL NEUROKININ 1 RECEPTOR ANTAGONIST COMPOUNDS

The present invention relates to a compound according to formula (A) wherein n is 1 or 2; R1 and R2 are independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, CD3 or halogen; R3 is hydrogen, C(=O)OR7 or C1-4 alkyl optionally substituted with hyd

TACHYKININ RECEPTOR ANTAGONISTS

The present invention relates to selective NK-1 receptor antagonists of Formula (I) or a pharmaceutically acceptable salt thereof, for the treatment of disorders associated with an excess of tachykinins.

Quantitative structure-activity relationship of the mutagenicity of substituted N-nitroso-N-benzylmethylamines: Possible implications of carcinogenicity

The relative mutagenicities of substituted N-nitroso-N-benzylmethylamines have been reexamined from a quantitative structure-activity relationship point of view. Most of the compounds were mutagenic toward Salmonella typhimurium TA 1535 with Aroclor-induced male hamster liver S9 activation. The dose-response data were subjected to a multiple linear regression equation calculated in a stepwise manner, which found that the differences in mutagenicities could be explained primarily by differences in the three-bond path molecular connectivity index, with smaller contributions from σ and π. Moreover, a polynomial regression analysis showed that the maximum mutagenicity could be explained by an optimal amount of electron withdrawal by the substituent which could cause a weakening, or activation, of the methylene C-H bond. The possible relevance of these observations to carcinogenesis is discussed.

Benzylamines: Synthesis and evaluation of antimycobacterial properties

The synthesis of benzylamines with various N-alkyl chains and substituents in the aromatic system as well as their evaluation on Mycobacterium tuberculosis H 37 Ra are described. The most active compounds in this test, N-methyl-3-chlorobenzylamine (MIC 10.2 μg/mL), N-methyl-3,5-dichlorobenzylamine (93, MIC 10.2 μg/mL), and N-butyl-3,5-difluorobenzylamine (MIC 6.4 μg/mL), also exhibited a marked inhibitory effect on Mycobacterium marinum and Mycobacterium lufu used for the determination of antileprotic properties. The combination of 93 with aminosalicylic acid, streptomycin, or dapsone exert marked supra-additive effects on M. tuberculosis H 37 Ra.

Folate Antagonists. 18. Synthesis and Antimalarial Effects of N6-(Arylmethyl)-N6-methyl-2,4,6-pteridinetriamines and Related N6,N6-Disubstituted 2,4,6-Pteridinetriamines

N6-(Arylmethyl)-N6-methyl-2,4,6-pteridinetriamines (1-5) and related N6-substituted 2,4,6-pteridinetriamines (16-20) were obtained by the condensation of 6-chloro-2,4-pteridinediamine with methylarylmethanamine and other selected secondary amines.The requisite N-methylarylmethanamines (21-32) were prepared by the hydrogenation over Pt/C of the corresponding arylcarboxaldehyde in the presence of methanamine.Several of the N6-(arylmethyl)-N6-methyl-2,4,6-pteridinetriamines exhibited exceptional suppressive antimalarial activity against a drug-sensitive line of Plasmodium berghei in mice.N6-Methyl-N6-(1-naphthalenylmethyl)-2,4,6-pteridinetriamine (9), the most active of those compounds, was also shown to be curative at 3.16 mg/kg in a single oral dose against P. cynomolgi in the rhesus monkey.This compound was also shown to be effective against a chloroquine-resistant line of P. berghei in the mouse but showed cross-resistance to a pyrimethamine-resistant strain.Most of the 2,4,6-pteridinetriamines showed strong antibacterial action against Streptococcus faecalis and Staphylococcus aureus.